Oyster Point Pharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Oyster Point Pharma Inc (OYST) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Oyster Point Pharma Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 20M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+14.2% annualized vs trailing 12 months).
- Peer revenue share: Oyster Point Pharma Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
OYST Sales vs. its Competitors, Q3 2022
Oyster Point Pharma Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.8% year over year, combined, vs -68.8% for Oyster Point Pharma Inc. Oyster Point Pharma Inc's share of combined industry revenue moved from 0.05% to 0.01%, a loss of 0.04 percentage points.
Oyster Point Pharma Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Oyster Point Pharma Inc | - | - | - | Yes |
| High-Confidence Competitors (12) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
OYST Stock Performance relative to its Competitors
OYST Stock Performance relative to High-Confidence Competitors
Oyster Point Pharma Inc's Competitors Named by the Company
Competitive relationships identified from Oyster Point Pharma Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Lenz Therapeutics Inc | Company report | 85% |
| Halozyme Therapeutics Inc | Company report | 85% |
| Oculis Holding Ag | Company report | 85% |
| Tarsus Pharmaceuticals Inc | Company report | 85% |
| Ars Pharmaceuticals Inc | Company report | 85% |
| Agile Therapeutics Inc | Company report | 85% |
| AmerisourceBergen Corporation | Company report | 85% |
| Opus Genetics Inc | Company report | 85% |
| OCUP | Company report | 85% |
| Cardinal Health, Inc. | Company report | 85% |
| McKesson Corporation | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Titan Pharmaceuticals Inc | Company report | 85% |
| Amphastar Pharmaceuticals Inc | Company report | 85% |
| Amneal Pharmaceuticals Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Perrigo Company Plc | Company report | 85% |
| Aeon Biopharma inc | Company report | 85% |
| Verona Pharma Plc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Taro Pharmaceutical Industries Ltd | Company report | 85% |
| Dr Reddy s Laboratories Limited | Company report | 85% |
| Assertio Holdings inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Organon and Co | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Endo International Plc | Company report | 85% |
| Mallinckrodt Plc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Lannett Company Inc | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Eton Pharmaceuticals Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Collegium Pharmaceutical Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
Company report basis, confidence, active dates and source counts for Oyster Point Pharma Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.